Comprehensive Evaluation of Visual Function
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00894192|
Recruitment Status : Unknown
Verified May 2009 by The Chicago Lighthouse for People Who Are Blind or Visually Impaired.
Recruitment status was: Recruiting
First Posted : May 6, 2009
Last Update Posted : May 6, 2009
|Condition or disease||Intervention/treatment||Phase|
|Visual Function||Device: Izon Wavefront-guided lenses Device: Conventional lenses||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Comprehensive Evaluation of Visual Function|
|Study Start Date :||February 2009|
|Estimated Primary Completion Date :||October 2009|
|Estimated Study Completion Date :||December 2009|
|Active Comparator: Wavefront guided lenses||
Device: Izon Wavefront-guided lenses
Subjects will use prescribed eyeglasses for one week. Their visual functioning will be tested at the end of the week.
|Placebo Comparator: Conventional lenses||
Device: Conventional lenses
We will test the subjects with these lenses after they have worn them for one week. Same procedures will be followed as with the other lenses.
- Visual Acuity, and Contrast Sensitivity [ Time Frame: Once a week ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00894192
|Contact: Samar Suleman, BAfirstname.lastname@example.org|
|United States, Illinois|
|The Chicago Lighthouse||Recruiting|
|Chicago, Illinois, United States, 60608|
|Contact: Samar Suleman, BA 312-447-3234 email@example.com|
|Principal Investigator: Janet Szlyk, PhD|